Cellular senescence is a primary driver of biological aging
Neurological Relevance Preclinical evidence suggests broader neuroprotective potential: In traumatic brain injury models, SS-31 reduced mitochondrial swelling, neuronal loss, and neuroinflammation Aged mice treated with SS-31 showed significantly improved exercise tolerance, muscle strength, and mitochondrial efficiency Studies demonstrate protection against ischemic injury and enhanced cardiac output Phase 3 trials are ongoing for dry age-related macular degeneration and primary mitochondrial myopathy (Stealth BioTherapeutics pipeline) Implications for Brain Aging Mitochondrial dysfunction is a hallmark of brain aging and neurodegeneration
The safety profile of cagrilintide-semaglutide was broadly consistent with that reported for other incretin-based therapies, although gastrointestinal adverse events and treatment discontinuations occurred more frequently than with either semaglutide or cagrilintide alone, highlighting the importance of careful patient selection and long-term adherence
A typical flow for a patient entering this market with any digital health company looks something like this: Considering this, founders or companies that are looking to expand into this sector technically they need the following: Prescribing & Intake: The most efficient peptide platforms use an asynchronous "store-and-forward" model
Impact of dopamine oxidation on dopaminergic neurodegeneration
